Scarica l'app Stockscreener
46.96
0.76%
-0.36
Dopo l'orario di chiusura:
46.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Raised by Tidal Investments LLC - MarketBeat
Sanctuary Advisors LLC Purchases 16,511 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.11 - MarketBeat
Halozyme Therapeutics' (HALO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Wellington Management Group LLP Has $3.73 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
9 Analysts Have This To Say About Halozyme Therapeutics - Benzinga
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - MSN
Johnson & Johnson Rybrevant version rejected in US (JNJ:NYSE) - Seeking Alpha
Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035, Featuring Profiles of Halozyme, HNS, INOVIO Pharmaceuticals and Medical International Technology and PharmaJet - Yahoo Finance
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% - Yahoo Finance
Geode Capital Management LLC Purchases 30,901 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Retirement Systems of Alabama Purchases 74,173 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Trading (HALO) With Integrated Risk Controls - Stock Traders Daily
57,526 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by World Investment Advisors LLC - MarketBeat
Zacks Research Issues Optimistic Forecast for HALO Earnings - MarketBeat
Halozyme to Present at Upcoming Investor Conferences - The Eastern Progress Online
Q1 EPS Forecast for Halozyme Therapeutics Boosted by Analyst - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - The Eastern Progress Online
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - MSN
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? - Yahoo Finance
Hodges Capital Management Inc. Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pier Capital LLC - MarketBeat
Castleark Management LLC Takes $3.99 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Janus Henderson Group PLC Purchases 31,871 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now - Yahoo Finance
HALO vs. FOLD: Which Stock Is the Better Value Option? - Yahoo Finance
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Erste Asset Management GmbH Invests $2.72 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
94,009 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Bridgewater Associates LP Has $659,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Phase 2 Data in Advanced Pancreas Cancer Featured in an Oral Presentation at ASCO - Marketscreener.com
Edgestream Partners L.P. Purchases 46,352 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Hantz Financial Services Inc. Invests $9.26 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
CreativeOne Wealth LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer - MSN
Halozyme abandons Evotec bid - Speciality Chemicals Magazine
Townsquare Capital LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Glenmede Trust Co. NA Acquires 109,283 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly - Simply Wall St
Fisher Asset Management LLC Has $18.55 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
RPg Family Wealth Advisory LLC Purchases New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Swedbank AB Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Halozyme CEO and CFO to Present at Major Healthcare Investor Conferences in December - StockTitan
Halozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade) (HALO) - Seeking Alpha
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up - MSN
Halozyme abandons its €2bn pursuit of Evotec - pharmaphorum
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Intech Investment Management LLC - MarketBeat
Halozyme eyes continuous manufacturing platform in $2.1bn Evotec bid - BioProcess Insider
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):